Search
JSM 6427
go.drugbank.com/drugs/DB06139InvestigationalIt has been biologically validated for therapeutic use in the prevention and treatment of wet AMD, the leading cause of blindness in people over the age of 55.
Mazindol
go.drugbank.com/drugs/DB00579ApprovedIt inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter. … Mazindol is only approved in the United States for the treatment of Duchenne muscular dystrophy, and is not marketed or available in the United States for use in the treatment of obesity.
Rotigotine
go.drugbank.com/drugs/DB05271ApprovedInvestigationalIn 1998 Aderis licensed worldwide development and commercialization rights to Schwarz Pharma of Germany. It was approved by the European Medicines Agency in 2006 and by the FDA in 2007. … It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours.
Products: NEUPRO® 6 MG/24 H, NEUPRO® 4 MG /24 HPRO 2000
go.drugbank.com/drugs/DB05385InvestigationalPRO 2000 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials. … It is being studied for the prevention of HIV infection and other sexually transmitted diseases.
Categories: Compounds used in a research, industrial, or household settingAdrafinil
go.drugbank.com/drugs/DB08925ApprovedWithdrawnIt was marketed in France and elsewhere in Europe under the trade name Olmifon until September 2011 when France's FDA equivalent reassessed the drug and withdrew marketing permission. … It is also been used off-label to prevent fatigue or falling asleep for extended periods of time. Adrafinil does not currently have FDA approval and is thus unregulated in the United States.
Isoxsuprine
go.drugbank.com/drugs/DB08941ApprovedWithdrawnIts vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. It is used in the treatment of peripheral vascular disease and in premature labor.
Defactinib
go.drugbank.com/drugs/DB12282ApprovedInvestigational[L53208,A273943] Defactinib was approved by the US FDA in May 2025 in a co-package alongside [avutometinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian … signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, and its upregulation is a key resistance mechanism to MAPK inhibitors, facilitating tumor cell proliferation and survival in
Synonyms: N-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamideOleoyl-estrone
go.drugbank.com/drugs/DB04870InvestigationalIt has been shown in animal studies to promote the loss of body fat while maintaining body protein storage, maintaining nitrogen balance. … This hormone occurs naturally and is found circulating in various animal species and humans.
Masoprocol
go.drugbank.com/drugs/DB00179InvestigationalIt also serves as an antioxidant in fats and oils. [PubChem]
Categories: Compounds used in a research, industrial, or household settingFluticasone furoate
go.drugbank.com/drugs/DB08906ApprovedInvestigationalFluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications[FDA Label][F4364]. Fluticasone furoate was first approved in 2007[L5965].